Table 1: Clinical characteristics of B-NHL patients.
Figure S1: Flow cytometric analysis of FcγR expression in neutrophils before (A) and at day five after (B) rituximab treatment.FcγRI, FcγRII and FcγRIII expression were not altered by rituximab treatment in neutrophils (n = 15). Expression levels are displayed as median fluorescent intensity (MFI) in CD66b+ positive cells. A paired two-tailed student’s t-test was performed.
Figure S2: Flow cytometric analysis of FcγRIII expression in NK cells before (A) and at day five after (B) rituximab treatment. FcγRIII expression was not altered by rituximab treatment in NK cells (n = 12). Expression levels are displayed as median fluorescent intensity (MFI) in CD56+ positive cells. A paired two-tailed student’s t-test was performed.
Figure S3: S100A9 and S100A12 expression in neutrophils was increased after rituximab treatment. Flow cytometric analysis showed an increase in expression of S100A9 and S100A12 in neutrophils at day five after rituximab treatment (B) compared to the start of the treatment (A) (p = 0.023 and p = 0.008). Expression levels are displayed as median fluorescent intensity (MFI) in CD66b+positive cells. A paired two-tailed student’s t-test was performed (n = 15).